DeutschNewstral
Article
bizjournals.com on 2016-05-27 16:10
FDA rejects AstraZeneca's new drug application for blood disorder treatment
Related news
- FDA rejects Vanda’s drug application for jet lag disorderbizjournals.com
- FDA rejects AstraZeneca's experimental diabetes therapybizjournals.com
- FDA rejects J&J application for new rheumatoid arthritis treatmentbizjournals.com
- MUPDATE: Acorda Therapeutics shares crater 26% premarket after FDA rejects application for Parkinson's treatmentmarketwatch.com
- MRare blood clots tied to J&J's COVID-19 shot are similar to issues with AstraZeneca's vaccine, FDA official saysmarketwatch.com
- FFDA OKs First Treatment For Rare Genetic Disorderfultoncountynews.com
FDA OKs first treatment for rare genetic disordersmdailyjournal.com- FDA approves Acceleron's blood disorder drug ahead of schedulebizjournals.com
- FDA approves AstraZeneca's gout medicinebizjournals.com
- FDA rejects new drug application from Jupiter biotech firmbizjournals.com
FDA Rejects Bid To Authorize Cheap Antidepressant As Covid TreatmentForbes
FDA Rejects Oral Treatment for Type 1 Diabeteswsj.com
FDA authorizes AstraZeneca's COVID-19 antibody cocktailisraelnationalnews.com- MPalatin's stock rockets after FDA OK to market sexual desire disorder treatmentmarketwatch.com
- MAstraZeneca's Farxiga gets U.S. FDA approvalmarketwatch.com
- MCerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disordermarketwatch.com
- Vanda steps closer to potential FDA approval for rare developmental disorder treatmentbizjournals.com
- FDA rejects Trevena's new opioid pain drug application; stock falls by 35 percentbizjournals.com
- FDA rejects Recro Pharma new drug application for a non-opioid pain medicinebizjournals.com
Azar rejects claims Trump pressured FDA to approve convalescent plasma coronavirus treatmentFox News